STRATA Skin Sciences, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US86272A2069
USD
1.46
0.07 (5.04%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About STRATA Skin Sciences, Inc. stock-summary
stock-summary
STRATA Skin Sciences, Inc.
Pharmaceuticals & Biotechnology
STRATA Skin Sciences, Inc., formerly MELA Sciences, Inc., is a medical technology company. The Company is engaged in developing and commercializing products for the diagnosis and treatment of dermatological disorders. The Company has three segments: Dermatology Recurring Procedures, Dermatology Procedures Equipment and Dermatology Imaging. The XTRAC and VTRAC products are the devices used for the treatment of psoriasis, vitiligo and other skin disorders. The XTRAC system delivers targeted ultraviolet light to affected areas of skin, leading to psoriasis clearing and vitiligo repigmentation, following a series of treatments. The Company's technology includes XTRAC Excimer Laser, VTRAC Lamp and MelaFind. MelaFind is a non-invasive, point-of-care instrument to aid dermatologists in their decision to biopsy suspicious pigmented lesions, such as melanoma. The Company has approximately two distribution channels for phototherapy treatment equipment.
Company Coordinates stock-summary
Company Details
5 Walnut Grove Dr Ste 140 , HORSHAM PA : 19044-2252
stock-summary
Tel: 1 215 61932001 415 9375404
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 4 Schemes (2.82%)

Foreign Institutions

Held by 1 Foreign Institutions (0.01%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Dr. Uri Geiger
Chairman of the Board
Dr. Dolev Rafaeli
President, Interim Chief Executive Officer, Director
Mr. Samuel Navarro
Independent Director
Mr. Samuel Rubinstein
Independent Director
Mr. Nachum Shamir
Independent Director
Mr. David Stone
Independent Director
Ms. LuAnn Via
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
8 Million
(Quarterly Results - Jun 2025)
Net Profit:
-2 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 9 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

9.61

stock-summary
Return on Equity

-767.90%

stock-summary
Price to Book

9.17